2025 GIGA Annual Report | 49 INTERVIEW STRATEGIC DEVELOPMENT FOR GIGA PLATFORMS In 2024, the GIGA’s technology platforms experienced intense activity. An opportunity to take stock with Carine Bebrone, Director of GIGA Technology Platforms. What were the year’s major developments for the platforms? This year was marked by new acquisitions and technological advances. For example, we strengthened our infrastructures by adding new state-of-the-art equipment in fields such as cell imaging, flow cytometry, genomics and in vivo imaging. These investments enable us to remain at the cutting edge of technology and offer ever more effective services to meet the needs of researchers. On the methodological and technological front, we have made significant progress in several areas, notably in singlecell proteomics, high-resolution optical microscopy and the Genome Editing Platform, where 2024 saw the creation of the first Knock-In (KI) mouse lines using the CRISPR-Cas9 method in collaboration with the Animal Facility. Have collaborations within platforms been strengthened? Yes, and cross-platform interactions have been essential to the progress of several projects. For example, collaboration between the Immunohistology, Cell Imaging and Proteomics platforms has led to the implementation of a laser microdissection approach on 1000 µm² FFPE tissue, paving the way for more precise analyses. Similarly, spatial transcriptomics, which mobilizes four platforms (Immunohistology, Cell Imaging & Flow Cytometry, Genomics and Bioinformatics), is now establishing itself as a key technology for understanding the spatial organization of biological processes. Collaboration between the Animal Facility, the Faculty of Veterinary Medicine and the University Hospital’s nuclear medicine department has also been strengthened, fostering a more integrated approach to preclinical and transtional research.
RkJQdWJsaXNoZXIy MTk1ODY=